Estrella Immunopharma, Inc. ESLA
0.48
0.01
2.13%
as of 25 Sep
- Market cap
- $20.5M
- P/E
- 0.0×
Follow ESLA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
0.15 | 0.12 | 0.24 | 0.20 |
Net Debt/EBITDA |
0.34 | 2.26 | 0.84 | 0.07 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.15 | 0.29 | 2.92 | 0.77 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.02) | 0.00 | (0.16) | (0.04) | |
Cash per Share |
0.04 | 0.04 | 0.05 | 0.00 | |
Shareholders Equity per Share |
(0.27) | (0.28) | (0.13) | (0.17) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.27) | (0.28) | (0.13) | (0.17) | |
Free Cash Flow |
(0.73) | (0.18) | (6.70) | (1.78) | |
Working Capital |
(11.34) | (11.87) | (6.77) | (7.43) | |
Net Current Asset Value |
(11.34) | (11.87) | (6.77) | (7.43) | |
| Other line items | |||||
Quick Ratio |
0.12 | 0.10 | 0.22 | 0.02 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.02) | 0.00 | (0.16) | (0.04) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
0.01 | 0.28 | 0.01 | 0.01 | |
Average Assets |
3.63 | 3.16 | 3.05 | 2.40 | |
Average Common Equity |
(4.55) | (5.11) | (3.55) | (6.76) | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates